FME Stock Analysis: Fresenius Medical Care | XETRA
Medical Care Facilities | XETRA, Germany | Market Cap: 11.038m EUR | 12M Return: -8.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.8M
EPS Trend: 98.4%
Qual. Beats: 0
Rev. Trend: 4.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fresenius Medical Care AG (XETRA: FME), headquartered in Bad Homburg, Germany and incorporated in 1996, is a global provider of dialysis products and services for patients with kidney disease, operating primarily in Germany, the United States, and other international markets. The company runs an integrated business model through two segments: Care Delivery, which encompasses its network of outpatient dialysis clinics, hospital-based dialysis contracts, laboratory and diagnostic services, and home patient support; and Care Enablement, which develops, manufactures, and distributes hemodialysis machines, peritoneal dialysis cyclers, dialyzer solutions, bloodlines, renal pharmaceuticals, and water treatment systems. The vertical integration of clinic operations with proprietary equipment and supplies is a defining structural feature of the dialysis services industry, allowing operators to capture margin across both the service and consumable sides of treatment.
In addition to core dialysis, the company provides ancillary healthcare offerings such as vascular specialty services, ambulatory surgery centers, physician nephrology practice management, pharmacy, and the development, acquisition, and in-licensing of renal pharmaceuticals. Its products are sold to dialysis clinics, hospitals, and specialized treatment clinics, distributed through local sales forces as well as independent distributors, dealers, and sales agents. The GICS classification places the company within the Health Care Facilities sub-industry, reflecting the service-based nature of its primary revenue streams tied to chronic outpatient treatment of end-stage renal disease (ESRD) and acute kidney failure patients.
- US Care Delivery margins under pressure from rising labor costs
- CMS bundled reimbursement rate updates impact dialysis revenue
- Deleveraging progresses as Care Enablement segment growth accelerates
| Net Income: 945.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.45 > 1.0 |
| NWC/Revenue: 7.12% < 20% (prev 12.88%; Δ -5.76% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.75b > Net Income 945.1m |
| Net Debt (13.3b) to EBITDA (3.47b): 3.83 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (275.3m) vs 12m ago -6.19% < -2% |
| Gross Margin: 25.96% > 18% (prev 24.46%; Δ 1.50% > 0.5%) |
| Asset Turnover: 60.30% > 50% (prev 59.55%; Δ 0.76% > 0%) |
| Interest Coverage Ratio: 5.26 > 6 (EBIT TTM 2.01b / Interest Expense TTM 382.0m) |
| A: 0.04 (Total Current Assets 8.11b - Total Current Liabilities 6.73b) / Total Assets 31.5b |
| B: 0.39 (Retained Earnings 12.3b / Total Assets 31.5b) |
| C: 0.06 (EBIT TTM 2.01b / Avg Total Assets 32.1b) |
| D: 0.77 (Book Value of Equity 13.2b / Total Liabilities 17.3b) |
| Altman-Z'' = 2.79 = A |
| DSRI: 1.04 (Receivables 3.72b/3.59b, Revenue 19.4b/19.5b) |
| GMI: 0.94 (GM 24.46% / 25.96%) |
| AQI: 1.19 (AQ_t 0.65 / AQ_t-1 0.54) |
| SGI: 0.99 (Revenue 19.4b / 19.5b) |
| TATA: -0.06 (NI 945.1m - CFO 2.75b) / TA 31.5b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at EUR 42.29 with a total of 664,371 shares traded. Over the past week, the price has changed by +6.79%, over one month by +11.41%, over three months by +12.45% and over the past year by -8.26%.
Current recommended Stop Loss: 39.70 (which is 6.1% or 2.6 ATR below the current price).
Fresenius Medical Care has no consensus analysts rating.
P/E Trailing = 12.5688
P/E Forward = 9.99
P/S = 0.5702
P/B = 0.8346
P/EG = 0.8392
Revenue TTM = 19.4b EUR
EBIT TTM = 2.01b EUR
EBITDA TTM = 3.47b EUR
Long Term Debt = 5.74b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.39b EUR (from shortTermDebt, last quarter)
Debt = 14.5b EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.49b
Net Debt = 13.3b EUR (calculated: Debt 14.5b - CCE 1.24b)
Enterprise Value = 24.3b EUR (11.0b + Debt 14.5b - CCE 1.24b)
Interest Coverage Ratio = 5.26 (Ebit TTM 2.01b / Interest Expense TTM 382.0m)
EV/FCF = 13.62x (Enterprise Value 24.3b / FCF TTM 1.79b)
FCF Yield = 7.34% (FCF TTM 1.79b / Enterprise Value 24.3b)
FCF Margin = 9.22% (FCF TTM 1.79b / Revenue TTM 19.4b)
Net Margin = 4.88% (Net Income TTM 945.1m / Revenue TTM 19.4b)
Gross Margin = 25.96% ((Revenue TTM 19.4b - Cost of Revenue TTM 14.3b) / Revenue TTM)
Gross Margin QoQ = 25.57% (prev 27.40%)
Tobins Q-Ratio = 0.77 (Enterprise Value 24.3b / Total Assets 31.5b)
Interest Expense / Debt = 2.63% (Interest Expense 382.0m / Debt 14.5b)
Taxrate = 20.57% (302.2m / 1.47b)
NOPAT = 1.60b (EBIT 2.01b * (1 - 20.57%))
Current Ratio = 1.20 (Total Current Assets 8.11b / Total Current Liabilities 6.73b)
Debt / Equity = 1.10 (Debt 14.5b / totalStockholderEquity, last quarter 13.2b)
Debt / EBITDA = 3.83 (Net Debt 13.3b / EBITDA 3.47b)
Debt / FCF = 7.44 (Net Debt 13.3b / FCF TTM 1.79b)
Total Stockholder Equity = 13.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.94% (Net Income 945.1m / Total Assets 31.5b)
RoE = 7.16% (Net Income TTM 945.1m / Total Stockholder Equity 13.2b)
RoCE = 10.61% (EBIT 2.01b / Capital Employed (Equity 13.2b + L.T.Debt 5.74b))
RoIC = 6.10% (NOPAT 1.60b / Invested Capital 26.2b)
WACC = 3.99% (E(11.0b)/V(25.6b) * Re(6.48%) + D(14.5b)/V(25.6b) * Rd(2.63%) * (1-Tc(0.21)))
Discount Rate = 6.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.03 | Cagr: -2.80%
[DCF] Terminal Value 76.00% ; FCFF base≈1.76b ; Y1≈1.83b ; Y5≈2.08b
[DCF] Fair Price = 70.02 (EV 32.1b - Net Debt 13.3b = Equity 18.8b / Shares 268.6m; r=8.35% [WACC [floored]]; 5y FCF grow 4.38% → 2.50% )
EPS Correlation: 98.42 | EPS CAGR: 34.47% | SUE: -0.09 | # QB: 0
Revenue Correlation: 4.55 | Revenue CAGR: 0.03% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.17 | Chg30d=+2.15% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.16 | Chg30d=+2.60% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=3.93 | Chg30d=-0.22% | Revisions=-17% | GrowthEPS=-8.3% | GrowthRev=-0.9%
EPS next Year (2027-12-31): EPS=4.40 | Chg30d=-0.39% | Revisions=-46% | GrowthEPS=+12.2% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: -35% (up=5, down=12)